Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

  1. Hernández-Cruz, B.
  2. Otero-Varela, L.
  3. Freire-González, M.
  4. Busquets-Pérez, N.
  5. González, A.J.G.
  6. Moreno-Ramos, M.
  7. Blanco-Madrigal, J.M.
  8. Manrique-Arija, S.
  9. Perez-Pampin, E.
  10. Ruiz-Montesino, D.
  11. Sánchez-Alonso, F.
  12. Sanchez-Piedra, C.
  13. Castrejón, I.
Aldizkaria:
Annals of the Rheumatic Diseases

ISSN: 1468-2060,  0003-4967

Argitalpen urtea: 2024

Alea: 83

Zenbakia: 9

Orrialdeak: 1189-1199

Mota: Artikulua

DOI: 10.1136/ARD-2023-225271 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus